Uğur Chousein Efsun Gonca, Çörtük Mustafa, Cınarka Halit, Tanrıverdi Elif, Turan Demet, Yıldırım Binnaz Zeynep, Sezen Celal Buğra, Özgül Mehmet Akif
Clinic of Chest Diseases, University of Health Sciences, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.
Tuberk Toraks. 2020 Dec;68(4):371-378. doi: 10.5578/tt.70352.
The Severe Acute Respiratory Syndrome (SARS-CoV-2) virus, which emerged from China and spread all over the world, has affected the world in every aspect and will do so in the foreseeable future. This study was carried out to investigate the possible aggravating effect of smoking on the prognosis of patients with COVID-19 pneumonia presenting with pulmonary involvement.
114 adult patients who received inpatient treatment in our clinic with the diagnosis of COVID-19 pneumonia between 11 March 2020 and 30 April 2020 were retrospectively included in the study; in particular, they were evaluated in terms of smoking history, severity of disease, need for NIMV and ICU admission, and mortality during their hospitalization.
The mean age of the 114 patients hospitalized with COVID-19 pneumonia was 51.14 ± 14.97 (range 16-81), and 77 (67.5%) were male. Of the patients, 19 (15.9%) were active smokers, 23 were ex-smokers (20.1%), 72 (63.1%) non-smokers. The effect of smoking on the severity of the disease, length of hospitalization, need for non-invasive mechanical ventilation (NIMV) and intensive care unit (ICU) admission and mortality were not statistically significant.
The rate of active smoking in patients hospitalized with COVID- 19 is lower than the population average. In this study, no correlation was observed between smoking status and the severity, prognosis and mortality of the disease. Further studies with larger number of patients and case series are needed to better elucidate the relationship between smoking and COVID-19 and the pathophysiologic mechanisms of the effects of smoking on the natural history of COVID-19 pneumonia.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）自中国出现并蔓延至全球，在各个方面影响着世界，且在可预见的未来仍将如此。本研究旨在调查吸烟对出现肺部受累的新型冠状病毒肺炎（COVID-19）患者预后可能的加重作用。
回顾性纳入2020年3月11日至2020年4月30日期间在我院接受住院治疗且诊断为COVID-19肺炎的114例成年患者；具体而言，对他们的吸烟史、疾病严重程度、无创机械通气（NIMV）需求、入住重症监护病房（ICU）情况以及住院期间的死亡率进行了评估。
114例因COVID-19肺炎住院的患者平均年龄为51.14±14.97岁（范围16 - 81岁），其中77例（67.5%）为男性。患者中，19例（15.9%）为现吸烟者，23例（20.1%）为既往吸烟者，72例（63.1%）为非吸烟者。吸烟对疾病严重程度、住院时间、无创机械通气（NIMV）需求、入住重症监护病房（ICU）以及死亡率的影响无统计学意义。
COVID-19住院患者中的现吸烟率低于人群平均水平。本研究未观察到吸烟状况与疾病严重程度、预后及死亡率之间存在相关性。需要开展更多患者数量和病例系列的进一步研究，以更好地阐明吸烟与COVID-19之间的关系以及吸烟对COVID-19肺炎自然病程影响的病理生理机制。
